Chiesi Ltd is a patient focussed organisation committed to improving lives. To this end, we market products in several therapy areas: respiratory, neonatal, inflammatory and rare diseases.
Formoterol fumarate dihydrate and beclometasone dipropionate (Fostair®) is an inhaled corticosteroid and long-acting beta2-agonist, which employs Chiesi's unique Modulite® technology and is used for the regular treatment of asthma.
Launched in July 2006, beclometasone dipropionate (Clenil Modulite®) is used for the treatment of asthma. Employing Modulite® technology, Clenil supports seamless conversion to CFC-free inhalers in line with national Government strategy.
Formoterol fumarate dihydrate (Atimos Modulite®) is a long-acting beta2-agonist used for the treatment of conditions such as asthma or chronic obstructive pulmonary disease (COPD).
Tobramycin (Bramitob®) is used for the management of chronic pulmonary infection caused by Pseudomonas aeruginosa in cystic fibrosis.
Beclometasone dipropionate (Clipper®) is used to treat mild to moderate ulcerative colitis flares.
Poractant alfa (Curosurf®) is a natural surfactant used to prevent and treat respiratory distress syndrome in premature neonates.
For further information on our product portfolio please download the relevant Summary of Product Characteristics (SPC) or Patient Information Leaflet (PIL)
For further information regarding the Chiesi products available in Ireland, please visit www.medicines.ie